BioCardia Files 8-K: Reg FD Disclosure & Financials
Ticker: BCDA · Form: 8-K · Filed: Sep 18, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, regulation-fd
TL;DR
BioCardia dropped an 8-K with Reg FD and financials. Check it out.
AI Summary
BioCardia, Inc. filed an 8-K on September 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and headquartered in Sunnyvale, California.
Why It Matters
This filing provides important updates on BioCardia's regulatory compliance and financial reporting, which are crucial for investors to assess the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K for disclosures and financial statements, not indicating any immediate operational or financial distress.
Key Numbers
- 001-38999 — SEC File Number (Identifies the company's filing with the SEC)
- 23-2753988 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- September 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Sunnyvale, California (location) — Address of principal executive offices
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.
What financial statements are included in this filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific financial statements (e.g., balance sheet, income statement) are not detailed in the provided text.
When was BioCardia, Inc. previously known by another name?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc., with a date of name change on June 16, 2011.
What is the principal executive office address for BioCardia, Inc.?
The principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085.
What is the SIC code for BioCardia, Inc.?
The Standard Industrial Classification (SIC) code for BioCardia, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-18 07:00:10
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20250917_8k.htm (8-K) — 23KB
- ex_862597.htm (EX-99.1) — 16KB
- 0001437749-25-029347.txt ( ) — 171KB
- bcda-20250918.xsd (EX-101.SCH) — 3KB
- bcda-20250918_def.xml (EX-101.DEF) — 11KB
- bcda-20250918_lab.xml (EX-101.LAB) — 15KB
- bcda-20250918_pre.xml (EX-101.PRE) — 11KB
- bcda20250917_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 18, 2025, BioCardia, Inc. issued a press release announcing primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated September 18, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: September 18, 2025